STOCK TITAN

aTyr Pharma (ATYR) Stock Price, News & Analysis

ATYR NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
84 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
-44.2% close of May 12, 2026
1-year change
-81.7% closing prices, November 17, 2025 to November 17, 2026
1-month change
-28.3% closing prices, October 16, 2026 to November 17, 2026

Company Description

aTyr Pharma, Inc. (Nasdaq: ATYR) is a clinical stage biotechnology company focused on discovering and developing first-in-class medicines from a proprietary tRNA synthetase platform. According to the company’s disclosures, aTyr concentrates on translating tRNA synthetase biology into new therapies for fibrosis and inflammation, with a particular emphasis on serious lung diseases that involve chronic inflammation and progressive scarring.

aTyr describes tRNA synthetases as ancient, essential proteins that have evolved novel domains which regulate diverse pathways outside the cell in humans. The company’s discovery platform is built around a proprietary library of domains derived from all 20 human tRNA synthetases. By uncovering signaling pathways driven by these domains, aTyr aims to identify previously unrecognized therapeutic intervention points in immune-mediated and fibrotic diseases.

Core focus: interstitial lung disease and efzofitimod

aTyr’s lead therapeutic candidate is efzofitimod, which the company characterizes as a first-in-class or novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD). ILD is described in company materials as a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. aTyr highlights that these conditions often have limited therapeutic options and a need for safer, more effective, disease-modifying treatments that improve outcomes.

Efzofitimod is described as a tRNA synthetase–derived therapy that selectively modulates activated myeloid cells through neuropilin‑2 (NRP2) to resolve inflammation without immune suppression and with the potential to prevent progression of fibrosis. The company’s communications consistently position efzofitimod as the lead asset emerging from its tRNA synthetase platform.

Clinical programs and target indications

aTyr reports that efzofitimod is being evaluated in multiple clinical studies focused on forms of interstitial lung disease:

  • Pulmonary sarcoidosis: aTyr conducted a global Phase 3 interventional study known as EFZO‑FIT™ in 268 patients with pulmonary sarcoidosis, which the company describes as a major form of ILD. The study compared efzofitimod at 3.0 mg/kg and 5.0 mg/kg doses versus placebo over 48 weeks, with a protocol‑guided steroid taper. The primary endpoint was steroid reduction, measured as change from baseline in mean daily oral corticosteroid dose at week 48. The company has disclosed that the primary endpoint was not met, but that clinical improvements were observed across several pre‑specified efficacy parameters, including King’s Sarcoidosis Questionnaire (KSQ) scores, fatigue measures and measures related to steroid withdrawal, while lung function as measured by forced vital capacity was maintained and safety was generally consistent with prior trials.
  • Systemic sclerosis‑related ILD (SSc‑ILD): aTyr is also investigating efzofitimod in the Phase 2 EFZO‑CONNECT™ study in patients with limited or diffuse systemic sclerosis (scleroderma)–related ILD. Company disclosures describe this as a randomized, double‑blind, placebo‑controlled, 28‑week proof‑of‑concept study with three parallel cohorts dosed intravenously once monthly. Interim analyses reported by the company have highlighted stable or improved modified Rodnan Skin Score (mRSS) in all evaluated patients and a clinically important improvement in a subset of efzofitimod‑treated diffuse SSc‑ILD patients, as well as preliminary signals of improvement in selected inflammatory and disease biomarkers, with efzofitimod generally safe and well tolerated at the doses studied.

Across these programs, aTyr emphasizes the potential for efzofitimod to address quality of life measures, steroid burden and lung function in immune‑mediated fibrotic lung diseases, while acknowledging in its forward‑looking statements that clinical development outcomes and regulatory paths remain uncertain.

Discovery platform and pipeline beyond efzofitimod

Beyond its lead candidate, aTyr describes a broader discovery platform focused on tRNA synthetase biology. The company states that this platform is aimed at “unlocking hidden therapeutic intervention points” by uncovering signaling pathways driven by domains derived from all 20 tRNA synthetases.

As part of this platform, aTyr has disclosed advancement of ATYR0101 to investigational new drug (IND) candidate stage for pulmonary fibrosis. ATYR0101 is described as a fusion protein derived from a proprietary extracellular domain of aspartyl‑tRNA synthetase (DARS) that binds to latent transforming growth factor beta binding protein 1 (LTBP‑1) to induce cell death of myofibroblasts, which the company identifies as key cells responsible for driving progression of fibrosis. aTyr has indicated plans to pursue an IND filing for ATYR0101 on a future timeline set out in its communications.

Public company status and market visibility

aTyr’s common stock trades on the Nasdaq Capital Market under the symbol ATYR. The company has announced that it is a clinical stage biotechnology issuer and has reported periodic financial results, including research and development expenses primarily related to its efzofitimod clinical trials and discovery programs, as well as general and administrative expenses. In a corporate update, aTyr also disclosed that it was added to the Russell 2000® Index and the broader Russell 3000® Index as part of an annual reconstitution of those benchmarks, reflecting its inclusion among U.S. public companies tracked by those indices.

aTyr has also reported the use of equity‑based compensation, including stock options granted under an inducement plan pursuant to Nasdaq Listing Rule 5635(c)(4), as part of its approach to attracting and retaining employees in a research‑intensive environment.

Scientific and clinical engagement

The company regularly highlights its participation in scientific and medical forums. Disclosures reference presentations at meetings such as the European Respiratory Society (ERS) Congress, where aTyr presented additional findings from the EFZO‑FIT™ study, and specialized meetings on aminoacyl‑tRNA synthetase research, where the company has discussed advancement of its therapeutic platform for fibrotic lung diseases. aTyr also notes presentations at investor‑focused healthcare conferences and respiratory innovation meetings, where it provides updates on its clinical programs and discovery efforts.

Risk and forward‑looking considerations

aTyr’s public communications include detailed forward‑looking statements that outline the uncertainties inherent in drug discovery and development. The company notes risks related to reliance on third‑party partners, the evolving understanding of NRP2 and tRNA synthetase biology, potential delays in clinical trials, regulatory uncertainties, the possibility that clinical or other data may not support further development, the potential need to cease or delay development activities for existing or future product candidates, and the need to secure additional funding for its business and product development plans. These statements underscore that while aTyr is advancing a platform based on tRNA synthetase biology and clinical candidates targeting fibrotic lung diseases, outcomes for these programs are not assured.

Summary

In summary, aTyr Pharma is a Nasdaq‑listed, clinical stage biotechnology company centered on a proprietary tRNA synthetase–based discovery platform and a lead clinical candidate, efzofitimod, in development for forms of interstitial lung disease such as pulmonary sarcoidosis and systemic sclerosis‑related ILD. The company’s disclosures emphasize its focus on fibrosis and inflammation, its exploration of novel extracellular functions of tRNA synthetases, and its efforts to translate this biology into potential new therapies for patients with limited treatment options.

Stock Performance

$4.19
-16.03%
-0.80
Last updated: at
-81.7%
Performance 1 year
$10.7M

aTyr Pharma (ATYR) closed at $4.99 on November 17, 2026. Over the past 12 months, the price has lost 81.7%.

See what a $1,000 investment in ATYR would be worth today

Average down calculator for ATYR

ATYR Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

aTyr Pharma has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include conferences, earnings, clinical trial, stock split, partnership. View all ATYR news →

Financial Highlights

aTyr Pharma generated $190K in revenue in FY2025, operating income reached -$77.6M, and net income was -$74.1M. Diluted earnings per share stood at -$32.00. The company generated -$62.0M in operating cash flow. The current ratio was 5.30, measuring current assets divided by current liabilities.

$190K
Revenue (FY2025)
-$74.1M
Net Income (FY2025)
-$62.0M
Operating Cash Flow

Upcoming Events

DEC
03
December 3, 2026 Marketing

Piper Sandler fireside chat

CEO fireside chat at Piper Sandler 38th Annual Healthcare Conference in New York; live webcast and 90-day replay on investor site.
Q1
2027
Q1 2027 Clinical

EFZO-CONNECT topline data

Topline results from Phase 2 EFZO-CONNECT study in SSc-ILD expected in Q1 2027 (Jan 1–Mar 31, 2027 window).
YEAR
2027
2027 Clinical

Begin clinical trials

aTyr to advance ATYR0101 into clinical testing in 2027 to support an IND; timing depends on preclinical work and regulatory review.
FEB
17
February 17, 2027 Corporate

25% options vest

25% of 12,200 options vest for two new employees; $0.98 exercise price
FEB
17
February 17, 2027 - February 17, 2030 Corporate

Monthly vesting period

Remaining 9,150 options vest monthly through 2030-02-17; $0.98 exercise price
Q2
2027
Q2 2027 Clinical

EFZO-CONNECT results

Full Phase 2 EFZO-CONNECT study results for systemic sclerosis-related ILD expected in Q2 2027; timing subject to company release.

aTyr Pharma has 6 upcoming scheduled events. The next event, "Piper Sandler fireside chat", is scheduled for December 3, 2026 (in 15 days). Investors can track these dates to stay informed about potential catalysts that may affect the ATYR stock price.

Short Interest History

Last 12 Months

Short interest in aTyr Pharma (ATYR) currently stands at 293.4 thousand shares, representing 11.5% of the float. A stock split fell inside this reporting period, so the figure cannot be compared with the previous one.

Days to Cover History

Last 12 Months

Days to cover for aTyr Pharma (ATYR) currently stands at 3.4 days, down 37.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 63.5%. Across the settlements charted above, it has ranged from 1.0 to 25.3 days.

ATYR Company Profile & Sector Positioning

aTyr Pharma (ATYR) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing ATYR often look at related companies in the same sector, including Tvardi Therapeutics, Inc. (TVRD), Jasper Therapeutics, Inc. (JSPR), Actuate Therapeutics, Inc. (ACTU), Acumen Pharmaceuticals, Inc. (ABOS), and Allarity Therapeutics, Inc. (ALLR). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ATYR's relative position within its industry.

Frequently Asked Questions

The current stock price of aTyr Pharma (ATYR) is $4.19 as of November 18, 2026.

The market cap of aTyr Pharma (ATYR) is approximately $10.7M. Learn more about what market capitalization means .

The FY2025 revenue of aTyr Pharma (ATYR) is $190K, from its most recent completed fiscal year.

The FY2025 net income of aTyr Pharma (ATYR) is -$74.1M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of aTyr Pharma (ATYR) is -$32.00 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of aTyr Pharma (ATYR) is -$62.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of aTyr Pharma (ATYR), current assets divided by current liabilities, was 5.30 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of aTyr Pharma (ATYR) is -$77.6M for FY2025, its most recent completed fiscal year. Learn about operating income.

aTyr Pharma, Inc. is a clinical stage biotechnology company that focuses on discovering and developing first-in-class medicines from a proprietary tRNA synthetase platform. The company states that it is leveraging tRNA synthetase biology to create new therapies for fibrosis and inflammation, with a particular focus on interstitial lung disease.

aTyr’s lead therapeutic candidate is efzofitimod, which the company describes as a first-in-class or novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease. Efzofitimod is being studied in patients with pulmonary sarcoidosis and systemic sclerosis-related interstitial lung disease.

Company materials describe efzofitimod as a tRNA synthetase–derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2). aTyr states that this mechanism is intended to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis in interstitial lung diseases.

EFZO-FIT™ is a global Phase 3 randomized, double-blind, placebo-controlled study conducted by aTyr in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study evaluated efzofitimod at two dose levels versus placebo over 48 weeks, with a protocol-guided steroid taper. aTyr has reported that the primary endpoint of steroid reduction was not met, but that clinical improvements were observed in several pre-specified efficacy measures and that lung function was maintained.

EFZO-CONNECT™ is a Phase 2 randomized, double-blind, placebo-controlled proof-of-concept study sponsored by aTyr to evaluate the efficacy, safety and tolerability of efzofitimod in patients with limited or diffuse systemic sclerosis-related interstitial lung disease. The company describes it as a 28-week study with three parallel cohorts receiving intravenous efzofitimod at two dose levels or placebo once monthly.

According to aTyr, efzofitimod is in clinical development for interstitial lung disease, including pulmonary sarcoidosis and systemic sclerosis (scleroderma)-related interstitial lung disease. The company characterizes these as immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs and notes that current treatment options are limited.

aTyr describes its tRNA synthetase platform as a discovery engine based on a proprietary library of domains derived from all 20 human tRNA synthetases. The company states that these proteins have evolved novel extracellular domains that regulate diverse pathways, and its platform is focused on uncovering signaling pathways driven by these domains to identify new therapeutic intervention points for fibrosis and inflammation.

ATYR0101 is a fusion protein that aTyr has advanced to investigational new drug candidate stage for pulmonary fibrosis. The company describes ATYR0101 as derived from a proprietary extracellular domain of aspartyl-tRNA synthetase (DARS) that binds to latent transforming growth factor beta binding protein 1 (LTBP-1) to induce cell death of myofibroblasts, which it identifies as key cells driving the progression of fibrosis.

aTyr Pharma’s common stock trades on the Nasdaq Capital Market under the ticker symbol ATYR. The company has also reported its inclusion in the Russell 2000 Index and the Russell 3000 Index as part of an annual index reconstitution.

In its forward-looking statements, aTyr cites risks such as reliance on third-party partners, the incomplete understanding of NRP2 and tRNA synthetase biology, potential delays in clinical trials, regulatory uncertainties, the possibility that clinical or other data may not support further development of product candidates, the potential need to cease or delay development activities, and the need to raise additional funding for its business and product development plans.